Abbvie Inc

NYSE: ABBV
$189.45
-$0.23 (-0.1%)
Closing Price on October 29, 2024

ABBV Articles

courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull market is...
While it seems everything is fully priced, the good news for investors is that there is still a plethora of stocks that are cheaper than the overall S&P 500.
AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Monday include Albermarle, Blue Apron, Box, Dish Network, GM, Transocean and Under Armour.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring with the exception of the Nasdaq. Crude oil backed off after posting a few days...
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the report's top picks: AbbVie, Eli Lilly, Merck, and Shire.
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.